Screener
Sana Biotechnology SANA Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Sana Biotechnology in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Sana Biotechnology’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-216769
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $83,800 | $71,870 |
| Marketable securities | 17,336 | 66,512 |
| Restricted cash | 4,195 | 4,195 |
| Prepaid expenses and other current assets | 6,359 | 6,099 |
| Total current assets | 111,690 | 148,676 |
| Property and equipment, net | 25,673 | 26,906 |
Item 1. Financial Statements
FAQ
- What is Sana Biotechnology's cash & equivalents?
- Sana Biotechnology (SANA) reported cash & equivalents of $83.8M in Q1 2026.
- How has Sana Biotechnology's cash & equivalents changed year-over-year?
- Sana Biotechnology's cash & equivalents decreased by 12.8% year-over-year, from $96.13M to $83.8M.
- What is the long-term trend for Sana Biotechnology's cash & equivalents?
- Over 5 years (2020 to 2025), Sana Biotechnology's cash & equivalents has grown at a -10.5% compound annual growth rate (CAGR), from $124.81M to $71.87M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Sana Biotechnology's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude